Skip to main content

SCS as an Option for Chronic Low Back and/or Leg Pain Instead of Surgery

Completed · Not applicable · NCT04676022

Conditions: Chronic Pain

At a glance

Research payments reported, 2025
$136,893
U.S. investigators named
13
Sites paid
13
Planned or actual enrollment
241

About the trial

Sponsor
Boston Scientific Corporation
Tested
WaveWriter (device), Conventional Medical Managament (other)
Dates
Started 2021-03-26; completion 2025-02-21
Results posted
Yes

To evaluate the safety and effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities compared to Conventional Medical Management (CMM) in patients with chronic low back and/or leg pain who have not undergone spinal surgery when using the Boston Scientific WaveWriter SCS Systems.

From ClinicalTrials.gov, last updated 2025-03-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $136,893 in research payments for this study in 2025 (31 payments).

Products named: Precision

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Novant Medical Group Incorporated $42,716
  • University of Utah Hospital and Clinics, UT $16,098
  • Ochsner Medical Center Acute, LA $14,757
  • St Louis PAin Consultants LLC $14,603
  • Weill Cornell Medical College $11,340
  • Center for Clinical Research $9,000
  • Institute of Precision PAin Medicine PLLC $8,335
  • Velocity Clinical Research $6,585
  • Neurosurgery Foundation at Goodman Campbell $4,930
  • Carolinas Research Institute PLLC $2,990
  • Crimson PAin Management LLC $2,417
  • Dbps Research LLC $2,000
  • Charles R Gordon MD PA $1,122

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.